ACCRETION NUTRAVEDA IPO
Dhan Kirti is pleased to present an in-depth analysis of the upcoming Accretion Nutraveda Limited IPO. This highly anticipated public offering provides an opportunity for investors to engage with a prominent player in the rapidly expanding healthcare-focused Contract Development and Manufacturing Organization (CDMO) sector. Accretion Nutraveda Limited specializes in a diverse range of Ayurvedic and nutraceutical products, blending traditional wisdom with modern scientific advancements to cater to both domestic and international markets. As the company embarks on this significant growth phase, understanding its core business, financial health, strategic objectives, and potential risks becomes paramount for informed investment decisions.
Essential Details at a Glance
| IPO Period | 28th January 2026 – 30th January 2026 |
|---|---|
| Listing on | 04th February 2026 |
| Price Band | ₹122 – ₹129 per equity share |
| Lot Size & Minimum Investment | 1000 shares – ₹129,000 |
| Total Issue Size | INR 24.77 Crores |
The Accretion Nutraveda IPO is structured to raise capital for its ambitious expansion plans, reflecting its robust growth trajectory in the health and wellness industry. The set price band and lot size provide a clear entry point for prospective investors to participate in this offering.
Important Dates for Investors
- Opening Date: 28th January 2026
- Closing Date: 30th January 2026
- UPI Payment Deadline: 30th January 2026 (by 5 PM IST)
- Allotment Announcement: 02nd February 2026
- Refund Processing: 03rd February 2026
- Demat Credit: 03rd February 2026
- Stock Market Listing: 04th February 2026
- Mandate Validity End: 14th February 2026
- Anchor Investor Lock-in Release (50%): 04th March 2026
- Anchor Investor Lock-in Release (Remaining): 03rd May 2026
*Investors are advised to note that these dates are tentative and may be revised based on official notifications from the company or regulatory bodies. It is prudent to stay updated with the latest announcements.
Delving into Accretion Nutraveda Limited
Founded in 2021 as Accretion Nutraveda Private Limited and subsequently converted into a public limited company in 2025, Accretion Nutraveda Limited has rapidly established itself as a leading healthcare-focused Contract Development and Manufacturing Organization (CDMO). The company specializes in the manufacturing of a wide array of Ayurvedic and nutraceutical products, encompassing various dosage forms such as tablets, capsules, oral liquids, powders, oils, and external preparations.
Accretion Nutraveda’s operational philosophy is centered on harmonizing classical Ayurvedic knowledge with contemporary nutraceutical science. This unique approach allows the company to deliver highly customized manufacturing solutions that meet the evolving demands of its diverse clientele. The company caters to a broad spectrum of markets, serving domestic clients across India and extending its reach to international export destinations, including Sri Lanka, Singapore, and the USA. This global footprint underscores its capability to meet stringent international quality and regulatory standards.
Operating from a state-of-the-art, GMP and WHO-GMP certified leased manufacturing facility located in Gujarat, Accretion Nutraveda boasts advanced infrastructure and holds multiple quality certifications. This commitment to quality assurance is a cornerstone of its business model, which primarily revolves around contract manufacturing through domestic sales, merchant exports, and direct exports. The company benefits from an experienced promoter-led management team that maintains hands-on operational control. Furthermore, its strong relationships with established customers and suppliers have contributed to consistent revenue and profitability growth in recent years. With a diversified product portfolio, unwavering quality compliance, and a strategic focus on cultivating long-term partnerships, Accretion Nutraveda is well-positioned to capitalize on the robust growth opportunities within the Ayurvedic and nutraceutical manufacturing sector.
IPO Issue Structure and Capital Raise
| Total Funds Raised | INR 24.77 Crores |
|---|---|
| Fresh Issue Component | INR 24.77 Crores |
| Offer for Sale Component | Not Applicable |
The entire issue size of the Accretion Nutraveda IPO comprises a fresh issue of equity shares, aiming to raise INR 24.77 Crores. This indicates that the entirety of the proceeds from the IPO will directly flow into the company’s coffers, bolstering its financial capabilities for future growth and operational enhancements. Unlike an Offer for Sale (OFS), where existing shareholders sell their shares, a fresh issue signifies the company’s intent to infuse capital to fund its expansion plans, improve infrastructure, and strengthen its working capital base, ultimately benefiting its long-term prospects. This structure reflects a forward-looking strategy focused on internal growth and capacity building.
Strategic Utilization of IPO Proceeds
The capital raised through the IPO is earmarked for several strategic initiatives designed to enhance Accretion Nutraveda’s manufacturing capabilities, expand its operational footprint, and ensure sustained growth. The planned allocation of funds is detailed below:
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Purchase of machineries for automation in existing manufacturing unit | 4.22 | 17.04% |
| Purchase of machineries for new manufacturing setup | 8.03 | 32.43% |
| Working capital requirements | 5.50 | 22.21% |
| General corporate purposes | 7.02 | 28.32% |
A significant portion of the funds will be directed towards enhancing manufacturing infrastructure. This includes investing in automation for the existing unit, which is expected to boost efficiency, reduce operational costs, and increase production capacity. Furthermore, a substantial allocation for a new manufacturing setup signals the company’s commitment to scaling operations and meeting growing market demand. The allocation for working capital is crucial for day-to-day operational liquidity, supporting inventory management, raw material procurement, and other operational expenses. The remaining funds allocated for general corporate purposes provide the company with the flexibility to pursue strategic initiatives, undertake marketing activities, or address unforeseen business needs, ensuring adaptability and resilience in a dynamic market environment.
Core Strengths Driving Growth
Accretion Nutraveda Limited possesses several inherent strengths that underpin its market position and future growth potential:
- Diverse Ayurvedic and Nutraceutical Dosage Capabilities: The ability to manufacture a wide range of dosage forms, from tablets and capsules to oils and liquids, all under one facility, provides significant operational flexibility and a competitive edge in serving varied client needs.
- Strong CDMO Focus with Repeat Domestic and Export Clients: The company’s dedicated contract manufacturing model, combined with a strong base of recurring clients in both domestic and international markets, indicates high client satisfaction and stable revenue streams.
- Multiple Quality Certifications: Holding prestigious certifications such as WHO-GMP, FSSC 22000, and ISO standards underscores Accretion Nutraveda’s unwavering commitment to product quality, safety, and regulatory compliance, which is crucial in the healthcare sector.
- Experienced Promoter-Led Management: An active and seasoned promoter-led management team, with hands-on control over operations, ensures strategic vision, efficient execution, and agile decision-making, driving the company’s consistent performance.
- Consistent Revenue and Profitability Growth: The demonstrated track record of consistent growth in both revenue and profitability over recent years highlights the company’s robust business model, operational efficiency, and effective market penetration strategies.
Key Considerations and Potential Risks
While Accretion Nutraveda presents a compelling investment opportunity, potential investors should also be aware of certain risk factors:
- High Revenue Dependence on Domestic and Merchant Export Segment: A significant reliance on these specific segments for revenue generation could make the company susceptible to economic downturns or policy changes impacting these markets.
- Manufacturing Facility is Leased, Not Owned: Operating from a leased manufacturing facility, rather than an owned one, could entail risks related to lease renewals, rental increases, or potential operational disruptions if lease terms change unfavorably.
- Business Exposed to Regulatory Changes: The Ayurvedic and nutraceutical sectors are subject to evolving regulatory frameworks. Any stringent changes in regulations could impact product development, manufacturing processes, or market access, necessitating costly adaptations.
- Dependence on a Limited Number of Key Customers: A substantial portion of the company’s revenue might be derived from a few key customers. The loss of one or more of these major clients, or a significant reduction in their orders, could materially affect financial performance.
- Geographic Revenue Concentration: A significant portion of the company’s revenue is concentrated within Gujarat. While a strong base, this geographic concentration could expose the company to regional economic fluctuations or specific state-level policies, potentially limiting diversification benefits.
Subscription Performance Updates
As the Accretion Nutraveda IPO is currently upcoming, detailed subscription statistics will become available once the bidding period commences. Dhan Kirti will update this section with real-time subscription data for Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and Retail Individual Investors (RII) as soon as it is officially released. Investors are encouraged to monitor the subscription figures during the IPO period to gauge market interest.
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | (To be updated) | (To be updated) | (To be updated) |
| Non-Institutional Investors (NII) | (To be updated) | (To be updated) | (To be updated) |
| Retail Individual Investors (RII) | (To be updated) | (To be updated) | (To be updated) |
| Total | (To be updated) | (To be updated) | (To be updated) |
*Please note that any Grey Market Premium (GMP) figures are unofficial and subject to high volatility; investors should rely on official exchange data and company disclosures for reliable information.
Participating in the Accretion Nutraveda IPO
Investors keen on participating in the Accretion Nutraveda IPO can apply through the official Dhan Kirti IPO platform. Ensure your application is submitted before the subscription window closes on 30th January 2026. Reviewing the Red Herring Prospectus (RHP) thoroughly before applying is always recommended to make an informed investment decision.
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice. Investors should consult with a qualified financial advisor and conduct their own due diligence before making any investment decisions. Investment in IPOs carries inherent risks.
